Amedisys Inc (NASDAQ:AMED) Downgraded to Neutral at Mizuho
Amedisys Inc (NASDAQ:AMED) was downgraded by equities researchers at Mizuho from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, The Fly reports.
A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $57.00 target price on shares of Amedisys in a report on Friday, April 28th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a report on Monday, June 5th. Stephens raised their price target on Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a report on Thursday, May 4th. Finally, Benchmark Co. reaffirmed a “hold” rating and set a $57.00 price target (up from $50.00) on shares of Amedisys in a report on Wednesday, May 3rd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $58.38.
Amedisys (NASDAQ:AMED) opened at 59.41 on Wednesday. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The firm’s 50-day moving average price is $61.62 and its 200-day moving average price is $53.96. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of 44.01 and a beta of 0.94.
Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, May 2nd. The health services provider reported $0.47 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.06. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. The business had revenue of $370.46 million during the quarter, compared to analysts’ expectations of $370.03 million. During the same period in the prior year, the firm posted $0.33 EPS. Equities research analysts predict that Amedisys will post $2.08 earnings per share for the current year.
In related news, insider Scott G. Ginn sold 23,828 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $58.62, for a total transaction of $1,396,797.36. Following the completion of the sale, the insider now directly owns 13,018 shares of the company’s stock, valued at approximately $763,115.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lawrence R. Pernosky sold 11,500 shares of the firm’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $58.78, for a total value of $675,970.00. Following the sale, the insider now directly owns 30,093 shares of the company’s stock, valued at $1,768,866.54. The disclosure for this sale can be found here. Insiders have sold a total of 56,828 shares of company stock valued at $3,350,922 over the last ninety days. Insiders own 2.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in AMED. Russell Investments Group Ltd. purchased a new position in shares of Amedisys during the fourth quarter worth approximately $870,000. Thrivent Financial for Lutherans raised its position in shares of Amedisys by 6.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 15,133 shares of the health services provider’s stock worth $645,000 after buying an additional 880 shares during the last quarter. Norges Bank purchased a new position in shares of Amedisys during the fourth quarter worth approximately $13,483,000. Hudson Bay Capital Management LP purchased a new position in shares of Amedisys during the fourth quarter worth approximately $1,066,000. Finally, Bank of Montreal Can raised its position in shares of Amedisys by 8,881.4% in the first quarter. Bank of Montreal Can now owns 34,848 shares of the health services provider’s stock worth $1,780,000 after buying an additional 34,460 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.